Softwr

Healthcare · head to head

Clue vs PathAI

Clue logo

Clue

Healthcare

Period and cycle tracking app owned by German company Biowink, positioned around science based tracking and a published stance against sharing data with law enforcement

From
Free
Rated
-
Full reviewWebsite
PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite

The short version

  • Only Clue has a free tier, so it costs nothing to try first.
  • Each has a real cost: Clue clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.; PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • They diverge on capability: Clue covers Cycle and symptom tracking, PathAI covers AISight image management.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Clue and PathAI actually diverge.

Attributes where Clue and PathAI differ
AttributeCluePathAI
Starting priceFreeOn request
Pricing modelFree with a Plus subscriptionquote
Free tierYesNo
PlatformsiOS, AndroidWeb

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Clue

  • Cycle and symptom tracking
  • Cycle insights and patterns
  • Research partnerships
  • EU-based data hosting
  • Fertility and conception mode
  • Perimenopause and other life stage tracking

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

What people use each for

The jobs each tool is most often brought in to do.

Clue

  • Someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given Clues EU basis and published stance on law enforcement requestsnot PathAI
  • A user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community contentnot PathAI
  • A buyer comparing Clue directly against Flo on current published privacy policy language before choosing which app to trustnot PathAI
  • Someone tracking perimenopause or other non-standard cycle stages that some period apps do not support wellnot PathAI

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Clue
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Clue
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Clue
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Clue

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Clue

  • Clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.
  • Deeper cycle insights and predictions, the features most likely to justify tracking in the first place, are gated behind the Clue Plus subscription rather than fully free.
  • Being a smaller company than some competitors, Clue has less capital and legal resource to contest large-scale legal requests than a larger, better-funded rival might, despite its stated intent to do so.
  • Research partnerships using anonymised user data, while opt-in, still mean user-derived data can be used in ways beyond direct app functionality, and users should check current consent settings.
  • Cycle predictions rely on self-reported data and general population models, so accuracy for irregular cycles or specific medical conditions remains limited regardless of which app is used.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Pricing, plan by plan

Clue

Free
  • Clue Plus$9.99/month
    • Free tier covers core cycle tracking, logging and basic predictions
    • Clue Plus adds deeper cycle insights, extended predictions and personalised content
    • Annual Plus plans typically offered at a lower effective monthly rate

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Which should you pick?

Choose Clue if

  • You need cycle and symptom tracking.
  • You want to start without paying.
  • You work on iOS, Android.
  • You also want cycle insights and patterns.
Clue review

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Questions people ask

Is Clue or PathAI better?
Neither clearly leads. Clue starts at Free and PathAI at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Clue or PathAI?
Clue has a free tier; the other does not. Paid plans start at Free for Clue and On request for PathAI.
Does Clue or PathAI run on more platforms?
Clue runs on iOS, Android. PathAI runs on Web.
Can I use Clue for free?
Yes. Clue has a free tier, so you can try it without paying. PathAI starts at On request.
What is Clue best used for?
Clue is most often used for someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given clues eu basis and published stance on law enforcement requests, a user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community content, a buyer comparing clue directly against flo on current published privacy policy language before choosing which app to trust, someone tracking perimenopause or other non-standard cycle stages that some period apps do not support well. Of those, someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given clues eu basis and published stance on law enforcement requests and a user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community content are not what PathAI is typically brought in for.
What can Clue do that PathAI cannot?
Clue covers Cycle and symptom tracking, Cycle insights and patterns, Research partnerships, EU-based data hosting. PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

Clue: Does Clue share data with law enforcement?

Clue publishes a policy stating it does not share health data with law enforcement or public authorities without a legally binding request and states it will challenge requests it considers improper. This is the companys stated position; verify the current policy directly for specifics.

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Clue: Why does Clue emphasise being an EU company?

Clue operates under EU GDPR data protection rules and states this legal basis makes it harder for authorities outside the EU, including US authorities, to compel data disclosure than for a company based in the US.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Clue: Is Clue free?

Core cycle tracking, logging and basic predictions are free. Deeper insights and extended predictions require Clue Plus.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on Clue

More on PathAI

Keep looking

Other head to heads